Login
Navigate Fool.com
Will GRFS beat
the market?

Grifols, S.A. (ADR)

NASDAQ: GRFS

Community Rating: 2 Stars: Unattractive

26.93 -0.06 (-0.22%)

Quote as of

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $26.89
Previous Close $26.99
Daily Range $26.47 - $27.00
52-Week Range $15.24 - $31.63
Market Cap $15.0B
P/E Ratio 0.00
Dividend (Yield) $0.00 (0.0%)
Volume 522,619
Average Daily Volume 683,887
Current FY EPS $1.37

How do you think GRFS
will perform against the market?

Top GRFS Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

Stocks Climb as Optimism Surrounding Europe Returns

Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop a

Pre-Market Most Active for Mar 19, 2013 : BAC, NOK, ERIC, TWO, CHL, GRFS, LULU, HPT, SIRI, DELL, HN

Pre-Market Most Active for Mar 19, 2013 : BAC, NOK, ERIC, TWO, CHL, GRFS, LULU, HPT, SIRI, DELL, HNR, QQQ

Billionaire John Paulson’s New Stock Picks

JDA Software Group and Sirius XM Radio Among Most Active Stocks in Nasdaq Pre-Market

Grifols was up this morning.

Pre-Market Most Active for Nov 1, 2012 : JDAS, SIRI, BAC, NOK, CBB, SNY, PHG, GRFS, PFE, AAPL, ASML

Pre-Market Most Active for Nov 1, 2012 : JDAS, SIRI, BAC, NOK, CBB, SNY, PHG, GRFS, PFE, AAPL, ASML, QQQ

Stop Vampires from Sucking your Portfolio Dry

3 Stocks Set to Beat the S&P Today

3 Stocks Set to Beat the S&P Today

Friday's Impetus Wanes as China Leads Direction

See More GRFS News...

Sector

Healthcare

Industry

Healthcare Information Services

Grifols, S.A. (ADR) (GRFS) Description

Grifols S.A. is engaged in the research development manufacture and marketing of plasma derivatives IV therapy enteral nutrition diagnostic systems and medical materials. Website: http://www.grifols.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks